Drug intelligence / Profile preview

RP1208

Development stage: Preclinical
Lead developer: Reviva Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

RP1208 is a novel **triple reuptake inhibitor** developed by Reviva Pharmaceuticals for the potential treatment of depression and obesity. It acts by antagonizing or inhibiting the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). This mechanism is expected to enhance synaptic concentrations of dopamine, norepinephrine, and serotonin, aligning its pharmacology with antidepressant and anti-obesity effects. RP1208 is an in-house discovered new chemical entity and is currently in preclinical development as a chemical drug.

Other names: RP1208RP-1208RP 1208

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on RP1208.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RP1208.

Explore the full profile